Genus fast-tracks Chinese porcine JV with BCA: what changed and why it matters
Genus PLC has accelerated plans to form its Chinese porcine joint venture with Beijing Capital Agribusiness (BCA) and, crucially, is pulling forward cash. The new deal structure sees BCA take 51% of PIC China, with Genus retaining 49% and keeping royalties on the PRRS Resistant Pig (PRP) once commercialised.
The headline: Genus expects to receive US$160m gross cash (estimated US$140m net after withholding tax and costs) plus a US$7.5m milestone payment on regulatory sign-off for the JV formation. The transaction is expected to complete in 2026, subject to Chinese approvals.
Deal mechanics and cash inflow: the numbers you need
The updated agreements accelerate value crystallisation for Genus while keeping future economic rights (royalties and dividends) consistent with the original 2019 terms. Here’s the core of it:
- BCA to own 51% of PIC China; Genus to own 49%.
- Genus to receive US$160m gross cash (estimated US$140m net, subject to working capital and net debt adjustments).
- US$7.5m accelerated milestone, paid on approval for JV formation by the competent Chinese state-owned assets supervision and administration authority, replacing remaining milestone payments under the old deal.
- Genus keeps intellectual property royalties on PRP sales in China and dividends from its 49% stake – exact rates not disclosed.
| Item | Detail |
|---|---|
| Ownership split | 51% BCA / 49% Genus |
| Cash to Genus (gross) | US$160m |
| Estimated net to Genus | US$140m (after withholding tax and costs) |
| Accelerated milestone | US$7.5m (on JV formation approval) |
| Royalties | On PRP sales in China (rates not disclosed) |
| Dividends | Based on 49% ownership |
| Target completion | 2026 (Stage 1 expected in FY26) |
Two-stage completion and the regulatory path in China
The transaction runs in two stages. Stage 1: PIC receives the US$7.5m milestone and US$160m cash; BCA acquires 51% of PIC China by buying existing shares and subscribing for new ones. This stage requires Chinese regulatory approvals and is expected in FY26.
Stage 2: PIC China acquires 100% of BCA’s Future Bio-Tech (FBT) – the entity spearheading PRP approval with MARA (China’s Ministry of Agriculture and Rural Affairs) under licence from Genus. BCA funds this entirely from its share subscription. Stage 2 is expected in 2026 and does not require further regulatory approval.
Why this is smart for PRP commercialisation in China
PRRS is a major disease challenge for pig herds, and Genus’s PRP is a gene-edited pig line designed to resist it. In China – which produces and consumes roughly half of the world’s pork according to BCA’s CEO – commercialisation hinges on local regulatory and political alignment.
Putting PIC China under a domestic state-backed partner (BCA) is, in Genus’s words, “the best possible route” to MARA approval. That matters because PRP is potentially transformative for productivity, animal health, and costs in China’s massive pork market.
Financial reporting impact: deconsolidation and capital allocation
Post-completion, PIC China will be deconsolidated from Genus’s financials. Instead, Genus’s 49% stake will be equity accounted – so expect lower reported revenue, but an ongoing share of profit plus China PRP royalties and dividends if and when commercialisation hits scale.
Management intends to use proceeds for balance sheet deleveraging and potential additional shareholder returns, consistent with its capital allocation framework. The precise form and timing of any extra returns are not disclosed.
Valuation context: cash versus book value and PIC China’s current scale
As at 30 June 2025, the total book value of net assets attributable to PIC China was approximately £32m. In the twelve months to 30 June 2025, revenue of £41.3m and adjusted operating profit including joint ventures of £8.4m were attributable to PIC China.
Set against that, the US$160m gross payment and US$7.5m milestone look like a material crystallisation of value ahead of PRP approval. Genus gives up control, but keeps a 49% stake plus future royalties and dividends – providing ongoing economic exposure if PRP scales in China.
What to watch from here
- Regulatory approvals: the JV formation needs sign-off from the relevant Chinese state-owned assets authority; PRP commercialisation requires MARA approval.
- Timing: Stage 1 targeted for FY26; Stage 2 during 2026; full completion expected in 2026.
- Cash receipt: US$160m gross and US$7.5m milestone tied to Stage 1 completion and approval conditions.
- Working capital/net debt adjustments: these could tweak the net cash received.
- Royalty detail: rates and mechanics are “consistent with the original agreements”, but not disclosed publicly.
- Financial presentation: watch for deconsolidation impacts on reported revenue and operating profit once the JV completes, with a shift to equity-accounted earnings.
- Capital allocation: management flags deleveraging first, with potential additional shareholder returns thereafter.
Josh’s take: a pragmatic China pivot with upfront cash and retained upside
On balance, this is a tidy piece of de-risking. Genus secures substantial upfront cash, aligns PIC China more tightly with a state-backed partner, and preserves the long-term economics of PRP through royalties and a 49% equity stake. For a programme where regulatory access is make-or-break, that’s sensible.
The flip side: Genus gives up control of PIC China and will deconsolidate the unit, which will likely reduce reported revenue once the deal closes. The full benefits still hinge on MARA approvals and successful PRP roll-out, which are not guaranteed. But the cash inflow – especially versus PIC China’s £32m book value – and the clearer route to market in the world’s largest pork economy make this a strategically positive move.
Jargon buster
- PRRS: Porcine Reproductive and Respiratory Syndrome, a virus that hits pig health and productivity.
- PRP: PRRS Resistant Pig – Genus’s gene-edited pig line designed to resist PRRS.
- MARA: China’s Ministry of Agriculture and Rural Affairs, the key regulator for agricultural biotech approvals.
- Deconsolidated: The business no longer sits within Genus’s consolidated revenue and profit; instead, Genus records its share of profits below the line.
- Equity accounted: Genus recognises its 49% share of the JV’s profit rather than consolidating 100% of revenue and cost lines.
- Withholding tax: Tax deducted at source in a cross-border payment before funds are remitted.
